It looks like your browser is not up to date.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Rize ICAV Medical Cannabis & Life Sciences UCITS ETF GBP (FLWG)

Sell:591.80p Buy:594.60p 0 Change: 20.40p (3.56%)
Market closed Prices as at close on 14 May 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:591.80p
Buy:594.60p
Change: 20.40p (3.56%)
Market closed Prices as at close on 14 May 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:591.80p
Buy:594.60p
Change: 20.40p (3.56%)
Market closed Prices as at close on 14 May 2021 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.
Open:
578.40p
Trade high:
594.89p
Year high:
815.80p
Market Listing:
London
Previous close:
572.80p
Trade low:
567.38p
Year low:
359.65p
Size:
$57.14M
Previous:
19.60p (3.31%)
Previous:
19.60p
Volume:
27,833
Dividend yield:
n/a
Currency:
GBX
Data delayed by at least 15 minutes.

ETP Basics

Issuer: Rize UCITS ICAV
Structure: ETF
Replication method: Stocks - Full Replication
Securities lending: No
Number of holdings: 32
Size: $57.1M
Launch date: 12 February 2020
Launch price: $5.04
UCITS: Yes
Reporting status: Yes
Domicile: Ireland
Sophisticated product: Non-sophisticated
ISIN: IE00BJXRZ273

Annual & interim reports

Ready to invest?

To buy shares in , you'll need to have an account.
Try our handy filter to explore the different options.

Compare accounts

Ready to invest?

To invest in , you'll need to open an account.
Try our handy filter to find which one suits you best.

Compare accounts

Important Documents

There are no documents available for this stock.

OBJECTIVE

Index: The Foxberry Medical Cannabis & Life Sciences Index provides exposure to companies involved in the global medical cannabis and cannabis-related life sciences sectors, with a focus on companies in the biotechnology/pharma and hemp and cannabidiol (CBD) sectors. The index excludes companies that are considered to be either non-compliant with state and federal laws in the countries in which they operate and/or directly involved in the production and/or distribution of cannabis and/or cannabis-derived products containing more than hemp-defined levels of tetrahydrocannabinol for the recreational consumer market. The index follows a modified liquidity-based weighting scheme where companies with higher liquidity achieve a bigger weight in the index
Aim: The Rize Medical Cannabis and Life Sciences UCITS ETF (FLWR) seeks to invest in...
Read full aim for Rize ICAV
Leverage: 100%
Currency hedging: No

COSTS

Ongoing Charge (OCF/TER): 0.65%
Management fee: 0.65%
Indicative spread: 0.47%

In certain cases, where no TER or OCF is shown, additional costs may apply. Please ensure you have read the Key Investor Information Document, Factsheet, Prospectus and any other relevant documentation prior to investing.

Performance

Not available for this stock.

Recent trade data is unavailable. We will be replacing it, however in the meantime the information is available on the London Stock Exchange website.

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Data provided by Funds Library. Some of the data on this page and other related pages is provided to you for your information and is received from the Fund Management Company administering this fund. Hargreaves Lansdown accepts no liability for the reliability or accuracy of the data provided by third parties. Securities lending data correct as at date not available. Charge data correct as at 31 March 2021. Holdings correct as at 30 April 2021.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.